This review elucidates the application of dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer, providing a comprehensive overview of the utilization and research advancements in dual ICI combination therapy in this context. Here, CD274 is linked to lung cancer.